



IPW

Docket No.: 21046-00053-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Norman J. Bennett et al.

Application No.: 10/551,235

Confirmation No.: 4118

Filed: September 27, 2005

Art Unit: 1632

For: USE OF ALLICIN AS PRESERVATIVE, AS  
DISINFECTANT, AS ANTIMICROBIAL OR  
AS BIOCIDAL AGENT

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 21046-00053-US1. A duplicate copy of this paper is enclosed.

Dated: *April 19, 2006*

Respectfully submitted,

By *Thor B. Nielsen*  
Thor B. Nielsen

Registration No.: 45,528  
CONNOLLY BOVE LODGE & HUTZ LLP  
1990 M Street, N.W., Suite 800  
Washington, DC 20036  
(202) 331-7111  
(Fax)  
Attorney for Applicant



Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Substitute for form 1449A/B/PTO				Complete if Known	
Sheet	1	of	2	Application Number	10/551,235
				Filing Date	September 27, 2005
				First Named Inventor	Norman J. Bennett
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	21046-00053-US1

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/C.S./	AA*	US-5 705 152-A	01-06-1998	Plummer	
/C.S./	AB*	US-5 906 825-A	05-25-1999	Craver	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> -Number-Kind Code <sup>3</sup> (if known)				
/C.S./	BA	WO-99/27940-A	06-10-1999	Yissum Research Development Co of the Hebrew Univ of Jerusalem		
/C.S./	BB	WO-97/39115	10-23-1997	Yeda Research and Development Co., Ltd.		
/C.S./	BC	WO-90/14012-A	11-29-1990	Ferrari		
/C.S./	BD	WO-03/024437-A1	03-27-2003	Stone Island Holdings LTD		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/C.S./	CA	Ankri et al., "Antimicrobial properties of allicin from garlic," <i>Microbes and Infection</i> , vol. 1, no. 2, Feb. 1999 (1999-02), pages 125-129	
	CB	McClure et al., "Effect of Medicinal plant extracts on the growth of Leishmania sp. and mammalian cell lines," <i>Abstracts of the General Meeting of the American Society of Microbiology</i> , vol. 94, no. 0, 1994, page 18	
	CC	McClure et al., "Antileishmanial properties of Allium sativum extracts and derivatives," <i>ACTA Horticulturae</i> , 426 (Int'l Symp on Medicinal and Aromatic Plants, 1995), 183-191	
	CD	Ghazanfari et al., "Garlic induces a shift in cytokine pattern in Leishmania major-infected BALB/c mice," <i>Scandinavian Journal of Immunology</i> , vol. 52, no. 5, Nov. 2000 (2000-11), pages 491-495	
	CE	Ledezma et al., "Antiproliferative and leishmanicidal effect of ajoene on various Leishmania species: Ultrastructural study," <i>Parasitology Research</i> , vol. 88, no. 8, August 2002 (2002-8), pages 748-753	
	CF	Ahmadi-Renani et al., "Effect of garlic extract on cutaneous leishmaniasis and the role of nitric oxide," <i>Iranian Journal of Medical Sciences</i> 2002 Iran, vol. 27, no. 3, 2002, pages 97-100	
	CG	Kunchong, "Chemical inhibition of <i>Ascophyllum nodosum</i> Olive & Spiltoir," <i>Entomological Knowledge</i> , 34(3), 163-163, 1997	
	CH	Sandhu et al., "Sensitivity of Yeasts Isolated From Cases of Vaginitis to Aqueous Extracts of Garlic," <i>Mykosen</i> , vol. 23, no. 12, 1980, pages 691-698	
/C.S./	CI	Farbman, "Antibacterial Activity of Garlic and Onions: A Historical Perspective," <i>Pediatric Infectious Disease Journal</i> , Williams & Wilkins, Balt., MD, US, vol. 12, no. 7, July 1, 1993, pages 613-614	
Examiner Signature	/Christopher Stone/		Date Considered
459405			11/13/2008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/551,235
<i>(Use as many sheets as necessary)</i>				Filing Date	September 27, 2005
				First Named Inventor	Norman J. Bennett
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	21046-00053-US1

/C.S./	CJ	Cutler et al., "Activity of a novel, stable, Allicin extract, in liquid and cream formulations, against methicillin resistant <i>Staphylococcus aureus</i> (MRSA) including mupirocin resistant MRSA," Interscience Conference on Antimicrobial Agents and Chemotherapy, vol. 41, 2001, page 201	
--------	----	--	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 459405	/Christopher Stone/	Date Considered	11/13/2008
------------------------------	---------------------	-----------------	------------